ConductScience.org, home

Paper36967770

The impact of SGLT2 inhibitors on αKlotho in renal MDCK and HK-2 cells.

Wolf L and 2 others. Front Endocrinol (Lausanne), 2023. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. The impact of SGLT2 inhibitors on αKlotho in renal MDCK and HK-2 cells. Papers, record 36967770. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36967770

Download JSON
Cell line
MDCK79 papers
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The impact of SGLT2 inhibitors on αKlotho in renal MDCK and HK-2 cells.
PubMed
Journal
Front Endocrinol (Lausanne)
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
0.93
iCite
Revised in PubMed
2026-01-27
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wolf LLisa
2Föller MMichael
3Feger MMartina

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Sodium-Glucose Transporter 2 InhibitorsMajor topic
Animals
Mice
Canagliflozin
Hypoglycemic Agents
Kidney
Hormones
Benzhydryl Compounds
Glucosides

Source PubMed

Download CSV of topics

References61

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127292223In vivo evidence for a limited role of proximal tubular Klotho in renal phosphate handling.Kidney Int2016https://conductscience.org/library/papers/27292223PubMed
232860942SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort studies.Pharmacol Res2020https://conductscience.org/library/papers/32860942PubMed
325527370Plasma fibroblast growth factor 23 and risk of cardiovascular disease: results from the EPIC-Germany case-cohort study.Eur J Epidemiol2015https://conductscience.org/library/papers/25527370PubMed
432996085SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes.Diabetes Ther2020https://conductscience.org/library/papers/32996085PubMed
528153033Klotho, an anti-aging gene, acts as a tumor suppressor and inhibitor of IGF-1R signaling in diffuse large B cell lymphoma.J Hematol Oncol2017https://conductscience.org/library/papers/28153033PubMed
631001673Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease.Diabetologia2019https://conductscience.org/library/papers/31001673PubMed
725695404Molecular basis of Klotho: from gene to function in aging.Endocr Rev2015https://conductscience.org/library/papers/25695404PubMed
827941935Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.Nat Rev Nephrol2017https://conductscience.org/library/papers/27941935PubMed
916436465Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process.FASEB J2006https://conductscience.org/library/papers/16436465PubMed
1023563279Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.Pharmacol Ther2013https://conductscience.org/library/papers/23563279PubMed
116178742The MDCK epithelial cell line expresses a cell surface antigen of the kidney distal tubule.J Cell Biol1982https://conductscience.org/library/papers/6178742PubMed
1229250031New Insights into the Mechanism of Action of Soluble Klotho.Front Endocrinol (Lausanne)2017https://conductscience.org/library/papers/29250031PubMed
1333637203Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.Kidney Int2021https://conductscience.org/library/papers/33637203PubMed
1436148061Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials.Front Cardiovasc Med2022https://conductscience.org/library/papers/36148061PubMed
1522878961Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism.J Am Soc Nephrol2012https://conductscience.org/library/papers/22878961PubMed
1635154011The Urinary Glucose Excretion by Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Different Levels of Renal Function: A Systematic Review and Meta-Analysis.Front Endocrinol (Lausanne)2021https://conductscience.org/library/papers/35154011PubMed
1732319182Klotho protein contributes to cardioprotection during ischaemia/reperfusion injury.J Cell Mol Med2020https://conductscience.org/library/papers/32319182PubMed
1835064106A Klotho-derived peptide protects against kidney fibrosis by targeting TGF-β signaling.Nat Commun2022https://conductscience.org/library/papers/35064106PubMed
1931862149Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.Lancet Diabetes Endocrinol2020https://conductscience.org/library/papers/31862149PubMed
2030519189Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients.Front Physiol2018https://conductscience.org/library/papers/30519189PubMed

See all 61 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
42511482Global Adam17 Deficiency Preserves Renal Function and Modulates Integrated Pathogenic Responses in Experimental Diabetic Kidney Disease.Int J Mol Sci2026https://conductscience.org/library/papers/42511482PubMed
41596241Chronic Kidney Disease in Metabolic Disease: Regulation of SGLT2 and Transcriptomic-Epigenetic Effects of Its Pharmacological Inhibition.Int J Mol Sci2026https://conductscience.org/library/papers/41596241PubMed
41316811Efficacy and safety of SGLT2 inhibitor on insulin resistance and hyperglycemia in Werner syndrome-A case report.J Diabetes Investig2026https://conductscience.org/library/papers/41316811PubMed
41010553Beyond the Cardio-Renal-Metabolic Axis: Emerging Therapeutic Targets and Novel Mechanisms of Action of Flozins.J Clin Med2025https://conductscience.org/library/papers/41010553PubMed
39409086SGLT2 Inhibitors and the Risk of Contrast-Associated Nephropathy Following Angiographic Intervention: Contradictory Concepts and Clinical Outcomes.Int J Mol Sci2024https://conductscience.org/library/papers/39409086PubMed
39200352Insulin Resistance, a Risk Factor for Alzheimer's Disease: Pathological Mechanisms and a New Proposal for a Preventive Therapeutic Approach.Biomedicines2024https://conductscience.org/library/papers/39200352PubMed
38454800SGLT2i improves kidney senescence by down-regulating the expression of LTBP2 in SAMP8 mice.J Cell Mol Med2024https://conductscience.org/library/papers/38454800PubMed

Download CSV of cited by

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36967770

GET https://conductscience.org/api/papers/v1/36967770/references?page=2